{
    "root": "350cfca7-2d28-84c4-e063-6294a90af068",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "PRAVASTATIN SODIUM",
    "value": "20250513",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM OXIDE",
            "code": "3A3U0GI71G",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31794"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "PRAVASTATIN SODIUM",
            "code": "3M8608UQ61",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8361"
        }
    ],
    "indications": {
        "text": "therapy lipid-altering agents one component multiple risk factor intervention individuals significantly increased risk atherosclerotic vascular disease due hypercholesterolemia . therapy indicated adjunct diet response diet restricted saturated fat cholesterol nonpharmacologic measures alone inadequate .",
        "doid_entities": [
            {
                "text": "vascular disease (DOID:178)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_178"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "adults : recommended starting dose 40 mg daily . 80 mg dose patients reaching ldl-c goal 40 mg. ( 2.2 ) significant renal impairment : recommended starting dose pravastatin 10 mg daily . ( 2.3 ) children ( ages 8 13 years , inclusive ) : recommended starting dose 20 mg daily . ( 2.4 ) adolescents ( ages 14 18 years ) : recommended starting dose 40 mg daily . ( 2.4 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "16.1 supplied pravastatin sodium tablets , uspare supplied : 10 mg tablets : white off-white , rounded , rectangular-shaped , biconvex tablets debossed \u201c b 10 \u201d one side plain side . suppliedin bottles 1000 \u2019 count ( ndc 71335-2298-1 ) , 500 \u2019 count ( ndc 71335-2298-2 ) . bottles contain desiccant canister . 16.2 storage store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . keep tightly closed ( protect moisture ) . protect light . repackaged/relabeled : bryant ranch prepack , inc. burbank , ca 91504",
    "adverseReactions": "hypersensitivity component medication . ( 4.1 , 6.2 , 11 ) active liver disease unexplained , persistent elevations serum transaminases . ( 4.2 , 5.3 ) pregnancy ( 4.3 , 8.1 , 8.3 ) lactation ( 4.4 , 8.2 )",
    "indications_original": "Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.",
    "contraindications_original": "Adults: the recommended starting dose is 40 mg once daily. Use 80 mg dose only for patients not reaching LDL-C goal with 40 mg. (2.2) Significant renal impairment: the recommended starting dose is pravastatin 10 mg once daily. (2.3) Children (ages 8 to 13 years, inclusive): the recommended starting dose is 20 mg once daily. (2.4) Adolescents (ages 14 to 18 years): the recommended starting dose is 40 mg once daily. (2.4)",
    "warningsAndPrecautions_original": "16.1 How Supplied\n                     \n                     Pravastatin Sodium Tablets, USPare supplied as:\n \n                  \n                     10 mg tablets:White to off-white, rounded, rectangular-shaped, biconvex tablets debossed with \u201cB 10\u201d on one side and plain on other side. They are suppliedin bottles of 1000\u2019s Count (NDC 71335-2298-1), 500\u2019s Count (NDC 71335-2298-2). Bottles contain a desiccant canister.\n \n                  \n                     16.2 Storage\n                     \nStore at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Keep tightly closed (protect from moisture). Protect from light.\n \n                  \n                  Repackaged/Relabeled by:\n  \nBryant Ranch Prepack, Inc.\n  \nBurbank, CA 91504",
    "adverseReactions_original": "Hypersensitivity to any component of this medication. (4.1, 6.2, 11) Active liver disease or unexplained, persistent elevations of serum transaminases. (4.2, 5.3 ) Pregnancy (4.3, 8.1, 8.3) Lactation (4.4, 8.2)",
    "drug": [
        {
            "name": "PRAVASTATIN SODIUM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8361"
        }
    ]
}